Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML
NCT04676243Phase 3Withdrawn
- Sponsor
- Heidelberg University Hospital
- Start
- May 2022
- Primary completion
- May 2025
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of quizartinib in acute myeloid leukemia (AML), sponsored by Heidelberg University Hospital. Planned start May 2022; status: withdrawn.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04676243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04676243.